Dyne Therapeutics, Inc. (DYN): Capital Expenditures
$1.92M
Year ended 2025-12-31
$2.61M
Trailing 12 months to 2026-06-30
-14.5%
3-year compound annual growth
+10.6%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.92M | -19.2% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $2.38M | +225.9% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $729.0K | -76.2% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $3.07M | -15.2% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $3.62M | +211.6% | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | $1.16M | -29.5% | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | $1.65M | n/a | 2021-03-04, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | 2025-12-31 | $1.92M | -19.2% |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $66.00M | +127.6% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $8.10M | +43.2% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $2.00M | -66.7% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $467.0K | -68.1% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $15.33M | +44.2% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $2.37M | -38.6% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $310.0K | -73.1% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $4.32M | +156.1% |
Compare DYN, INDV, ZLAB, RCUS side by side · Screen every company in Pharmaceutical Preparations ↗